We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
929 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
The name is from the Greek for evolution. Their game is comparitive genomics. They study fruit flies, nematodes, mice, zebrafish and simple plants to make predictions about function of human genes based on similarities between the species, or as they put it here: / Company Information,

they "take advantage of the evolutionary conservation of genes and gene function among diverse species." Now that we have working drafts of a human genome map, Exelixis should be well positioned as the focus shifts to determining gene function.

Address: 170 Harbor Way, South San Francisco, CA 94083

In its April 2000 IPO, the company sold 9.1 million shares @ $13.00

Last month, Exelixis completed the acquisition of a small agricultural biotech company, Agritope. This brings them expertise in higher plant model systems as well as key intellectual property and extensive experience in plant biology. Agritope develops improved plant products and has a subsidiary, Vinifera, "which propagates and markets grapevines to the U.S. premium wine grape production industry." Agritope will be renamed Exelixis Plant Sciences and will operate as a wholly-owned subsidiary.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
928Great data, however technical in the daily is still bearish. Need to hold $12.40more100-10/10/2016
927Another upgrade...... presstelegraph.comIsland Man-8/24/2016
926Should see 13 by labor day......then 15-16 thanksgiving unless of course a buyouIsland Man-8/22/2016
925Here's my synopsis on the weekly. Take it for what it's worth. I am longmore100-8/4/2016
924Same here. Tom Ntom n-7/12/2016
923Following you Ernie, I like SI better than IV.dartgator-7/12/2016
922Just testing this out to see if it is a viable alternative to the Yahoo Message erniewerner-7/12/2016
921Exelixis ($EXEL) announced positive updated results from a subgroup analysis of more100-1/5/2016
920big director buy here fwiw...mopgcw-12/11/2015
919$EXEL instead of 7.77 we are looking at 5.55. Talk about crooks of Wall Street. more100-11/12/2015
918I hadn't realized that the decision was only 5 weeks away. Roche says data Ian@SI-10/6/2015
917there still appears to be some buyers for this one, took some profits on my $2.mopgcw-4/14/2015
91617 Nov Exelixis, Inc. ( EXEL) today announced preliminary results from a phase nigel bates-11/17/2014
915fwiw, I am back in with some slugs at $3.45. call me crazy.mopgcw-7/17/2014
914Exelixis Announces Positive Top-Line Results for Phase 3 Pivotal Trial of Cobimenigel bates-7/14/2014
913Some IDIX magic rubbing off?tom pope-6/9/2014 "The results from the randomised Phase II part of the Phase I/II oscaram(o)uche-5/7/2014
911I think it will rebound seeing as EXEL has a lot going on this year but the stoctejek-3/26/2014
910Well, I jumped a trifle early at 4.50(!), small position, and then a larger onetom pope-3/26/2014
909now we know why it was only a 17 cent gain. Formal EU approval is a fait tejek-3/26/2014
908now we know why it was only a 17 cent gain. Formal EU approval is a fait aDewDiligence_on_SI-3/26/2014
907But is the fact that there is no near term gratification worth a 38% plunge? Ttejek-3/26/2014
906But is the fact that there is no near term gratification worth a 38% plunge?tom pope-3/26/2014
905and this was good for a 17 cent gain today... Well now we know why it was only tejek-3/26/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):